Published in:
Open Access 01-12-2016 | Editorial
Could we use a lower dose of rituximab to treat rheumatoid arthritis in clinical practice: pros and cons?
Published in: Arthritis Research & Therapy | Issue 1/2016
Login to get accessAbstract
The CERERRA database provides evidence that low-dose rituximab performs as well as the conventional dose in the real world, thus highlighting the possible pharmacoeconomic impact. In clinical trials, it has been shown that rituximab 500 mg twice, performs as well as 1 g twice, 2 weeks apart, in terms of the American College of Rheumatology (ACR)20 and ACR50, but not the ACR70. The choice should always be made after considering that the IMAGE trial has demonstrated similar radiographic progression after the first 6 months, but with less control, with low-dose rituximab in the first 6 months. A possible alternative can be hypothesized.